Cathay Securities and Haitong Securities: Initiates "Buy" rating on LEPU BIO-B, MRG003 expected to be approved domestically soon
I'm PortAI, I can summarize articles.
CITIC Securities has initiated coverage on LEPU BIO-B with a rating of "Buy" and a target price of RMB 9.55 / HKD 10.38. It is expected that the operating revenues for 2025-2027 will be RMB 853 million / RMB 1.204 billion / RMB 1.665 billion, respectively. The company's MRG003 is about to be approved and has established multiple oncology product pipelines, covering immunotherapy, ADC targeted therapy, and oncolytic virus drugs. MRG003 is expected to receive CDE priority review qualification in 2024 and submit NDA for review in 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments